6,678 trials
Smoking Cessation · Smoking · Nicotine Dependence
Primary: 7-Day Point-Prevalence Abstinence From Smoking — 27.8; 26.3; 30.5; 23.4 percentage of participants not smoking — p=.825
Anterior Cruciate Ligament Tear
Primary: International Knee Documentation Committee (IKDC) Form — 89; 88 score
BPH
Primary: Primary Outcome; International Prostate Symptom Score Changes Between 4 Groups Compared to Baseline After 12 mo Treatment — 13.0; 12.0; 10.6; 13.4 score — p=<0.05
Paget's Disease of the Bone · Hypocalcemia
Primary: Percentage of Patients With Serum Calcium <2.07 mmol/L at 9-11 Days After Receiving Zoledronic Acid. — 1.3; 0.0 percentage of patients
Irritable Bowel Syndrome
Primary: Colonic Compliance — 18.96; 16.86; 15.99; 15.75 mm Hg
HIV
Primary: Percentage of Participants With Plasma Human Immuno Deficiency Virus-1 Ribonucleic Acid (HIV-1 RNA) Load <50 Copies/Milliliter (mL) at 48 Weeks. — 77.92 Percentage of…
Type 2 Diabetes Mellitus
Primary: Comparison of Changes in Fasting Serum Glucose (FSG)With Pioglitazone and Metformin — 6.9; 6.2; 5.4; 6.5 mmol/l — p=<0.05
Diabetes Mellitus, Type 2
Primary: Change From Baseline to 24 Week Endpoint in Glycated Hemoglobin (HbA1c) — -1.00; -0.96; -0.98; -0.92 percentage HbA1c
Pill Capsule Endoscopy Completion Rates
Primary: Difference in Treatment vs. Placebo in Pill Capsule Completion Rates — 100; 0; 100 percentage of complete capsule studies
Parkinsons Disease With Dementia · Parkinsons Disease With Mild to Moderate Memory and/or Thinking Problems
Primary: Resting State Functional Activity Change From Baseline to 12 Weeks — 1.13; .79 z-score — p=<0.01
Pneumococcal Vaccines
Primary: Geometric Mean Concentration (GMC) for Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Infant Series — 1.64; 1.99; 1.48; 2.07 microgram…
Migraine Headache
Primary: Number of Subjects With at Least 50% Reduction in the Frequency of Days With Moderate or Severe Migraine in the 4 Week Post Injection Compared to the 4 Week…
Pre-eclampsia Aggravated
Primary: TOF 0.9 Achieving Time — 1.6; 2.1 minutes
Diabetes Mellitus, Type 2
Primary: Change in HbA1c From Baseline to 24 Weeks Endpoint (Per Protocol Population) — -1.30; -1.09 percentage of HbA1c
Allergic Rhinitis
Primary: Modified Epworth Sleepiness Scale — 6.14; 6.69; 7.48 units on a scale — p=.27